Disclosures for "Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial "
-
Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Elena Cortes-Vicente has received research support from UCB Pharma. The institution of Elena Cortes-Vicente has received research support from Instituto de Salud Carlos III (España).
-
Dr. Campbell has received personal compensation for serving as an employee of Johnson and Johnson.
-
Ms. Gandhi has received personal compensation for serving as an employee of Johnson and Johnson . Ms. Gandhi has stock in Johnson and Johnson .
-
Dr. Fitzgibbon has stock in Johnson & Johnson.
-
Ibrahim Turkoz has received personal compensation for serving as an employee of Johnson and Johnson. Ibrahim Turkoz has stock in Johnson and Johnson.